Oral anticancer agent medication adherence by outpatients - Wikidata - awgldk - TriplyDB

Oral anticancer agent medication adherence by outpatients

Oral anticancer agent medication adherence by outpatients

http://www.wikidata.org/entity/Q34293339

about

Oral antineoplastic agents: how do we care about adherence?Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer.

P2860

Q28082909-E5358554-6391-4365-8E69-BBA74DA198F6 Q35742246-F2C27F45-7A55-4886-ADAD-EDD893A2BE1C Q38637908-7787754D-B2A0-4C9C-80E8-3E24EFFF1F0A

P2860

Oral anticancer agent medication adherence by outpatients

http://www.wikidata.org/entity/Q34293339

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Oral anticancer agent medication adherence by outpatients

@ast

Oral anticancer agent medication adherence by outpatients

@en

Oral anticancer agent medication adherence by outpatients

@nl

type

label

Oral anticancer agent medication adherence by outpatients

@ast

Oral anticancer agent medication adherence by outpatients

@en

Oral anticancer agent medication adherence by outpatients

@nl

prefLabel

Oral anticancer agent medication adherence by outpatients

@ast

Oral anticancer agent medication adherence by outpatients

@en

Oral anticancer agent medication adherence by outpatients

@nl

P1433

Q34293339-FA962A0F-8ACB-4A0B-94E8-A70C6A794A41

P1476

Q34293339-C0D0C491-28BE-4467-83B3-930F5A14843E

P2093

Q34293339-11E58B22-2587-4ED3-B2A4-55FFC3E6C8BB

Q34293339-2DE619F6-AB6D-478B-9E09-7FDC37055F90

Q34293339-5C57C033-1464-4698-81EB-FCF540FA293C

Q34293339-7651B0EB-752B-4D0D-8036-6973F012CC8E

Q34293339-C34273F8-946E-4DD6-A455-6CBBB6079A3E

Q34293339-D85E832C-B4FC-4DCA-8467-CD9DBCB17290

Q34293339-DB931435-60A4-4AE6-8649-1EF6FFC8E8F3

Q34293339-DCE217E1-54D6-465B-B871-5AAFA8F6457B

P2860

Q34293339-0D694DE1-31AA-4ECD-B89B-3E145A4CCBDE

Q34293339-2819D62A-2FD7-4FC5-87C7-804A64B683EC

Q34293339-4C412214-B075-42EB-83C6-84441AAE4635

Q34293339-59CB107B-9C5E-4DBE-BA18-3B7EB06FB48D

Q34293339-5BC99583-8F4D-47E2-88CB-C9DF5F7B8961

Q34293339-9640278B-B853-463B-8BE8-C583FEF43931

Q34293339-98E96BE3-7504-478D-81D5-98F2CC633902

Q34293339-AD72F366-1050-4151-A021-78270029BBC6

Q34293339-B2C0C9F5-FB29-42A7-A833-41FFEBE2C580

Q34293339-B8E646FC-1BDF-4DEA-8091-30057D0C1B59

P304

Q34293339-06D6A57C-1F7C-4D9D-AA66-C1D0FBA9B822

P31

Q34293339-3AFB823E-9788-43B4-BBB2-31B3EC36CAFA

P356

Q34293339-5F5367F8-C081-4A94-B9CE-2A379236E530

P433

Q34293339-D88086AB-00C3-4037-A006-14C96C5E95D8

P478

Q34293339-42649790-1D06-4B10-A516-5A9D3FC86AE4

P577

Q34293339-D5C550E8-FD09-4DAF-AC31-7849A04CCADF

P5875

Q34293339-B56FDBA4-6D17-4454-90E2-5C34A6952EFD

P698

Q34293339-E3A3E85F-A301-4483-BA6B-48B6A435543C

P932

Q34293339-F6312FE6-AB7D-4CFF-A131-8BCBED4CDD39

P356

P1433

Oncology Letters

P1476

Oral anticancer agent medication adherence by outpatients

@en

P2093

Eiseki Usami

http://www.w3.org/2001/XMLSchema#string

Hiromi Mori

http://www.w3.org/2001/XMLSchema#string

Hitomi Teramachi

http://www.w3.org/2001/XMLSchema#string

Michio Kimura

http://www.w3.org/2001/XMLSchema#string

Mina Iwai

http://www.w3.org/2001/XMLSchema#string

Tadashi Sugiyama

http://www.w3.org/2001/XMLSchema#string

Tomoaki Yoshimura

http://www.w3.org/2001/XMLSchema#string

Toshiya Nakao

http://www.w3.org/2001/XMLSchema#string

P2860

Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study.

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer

Adherence and persistence: impact on outcomes and health care resources.

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

Patient adherence and persistence with oral anticancer treatment.

Nonadherence in patients with breast cancer receiving oral therapies.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

P304

2318-2324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2014.2480

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266626984

http://www.w3.org/2001/XMLSchema#string

P698

25295117

http://www.w3.org/2001/XMLSchema#string

P932

4186627

http://www.w3.org/2001/XMLSchema#string